Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

Abroad (travel likely)RecruitingPHASE1

Conditions

Hepatic Impairment · Cirrhosis · Cholestatic Liver Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zydus US002, Indianapolis, Indiana, United States
Contact: Study coordinator (Mandy Cruz) · mandcruz@iu.edu

Study leads

Deven V Parmar, MD, FCP
Study Director
Zydus Therapeutics Inc.

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Hepatic Impairment · Cirrhosis

Abroad (travel likely)RecruitingPHASE1

Rialto, United States · Tustin, United States

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

Cholestatic Liver Disease

Abroad (travel likely)RecruitingPHASE1

Indianapolis, United States

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

Hepatic Impairment (HI)

Abroad (travel likely)RecruitingPHASE1

Miami, United States · Orlando, United States

A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function

Healthy Adult Participants · Hepatic Impairment (HI)

Abroad (travel likely)RecruitingPHASE1

Bengbu, China